Jonathan Staben, MD
Family Medicine · Cheney, WANPI 1720071889
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,675 of the $9,116 with a category attached, or 84.2%. AbbVie accounts for 96.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $7,998 and has fallen 87.2% since, to $1,025 in 2021. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $337.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Sanofi Pasteur Inc.$275
- Lilly USA, LLC$93
Across 427 payments — averaging $5815.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$997K
- Merck$722K
- Bavarian Nordic A/s$333K
- Janssen Research & Development, LLC$114K
- Novavax Inc$75K
- Organon$58K
- plus $184K from 6 others
What the payments were for
- Speaking & faculty fees$7,67584%
- Travel & lodging$87510%
- Food & beverage$5666%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $8,748 |
| Sanofi Pasteur Inc. | 1 | $275 |
| Lilly USA, LLC | 2 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,116 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $70,820 |
| OzempicSemaglutide | 35 | $52,218 |
| EliquisApixaban | 37 | $46,744 |
| XareltoRivaroxaban | 20 | $24,535 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,229 |
| Spiriva RespimatTiotropium Bromide | 13 | $15,809 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $10,804 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,086 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $9,013 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $8,561 |
| Gabapentin | 124 | $4,834 |
| Omeprazole | 253 | $4,192 |
| Atorvastatin Calcium | 300 | $3,488 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 183 | $3,318 |
| Levothyroxine Sodium | 273 | $3,291 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Cheney
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.